Presentation Slides
Back to course
Pdf Summary
Keywords
Clozapine
Pharmacodynamics
Pharmacokinetics
Treatment-resistant schizophrenia
Antagonist
Partial agonist
Bioavailability
CYP1A2 enzyme
Side effects
Patient outcomes
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
Powered By